You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 27, 2024

Details for Patent: 8,486,947

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,486,947 protect, and when does it expire?

Patent 8,486,947 protects WAKIX and is included in one NDA.

This patent has thirty-four patent family members in twenty-six countries.

Summary for Patent: 8,486,947

Title:	Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H.sub.3-receptor ligands
Abstract:	The present invention provides new method of treatment of Parkinson's disease, obstructive sleep apnea, narcolepsy, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamine derivatives that constitute antagonists of the H.sub.3-receptors of histamine.
Inventor(s):	Schwartz; Jean-Charles (Paris, FR), Lecomte; Jeanne-Marie (Paris, FR)
Assignee:	Bioprojet (Paris, FR)
Application Number:	11/909,778
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,486,947
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 8,486,947

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-001	Aug 14, 2019		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY	⤷ Sign Up
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-001	Aug 14, 2019		RX	Yes	No	⤷ Sign Up	⤷ Sign Up				METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY	⤷ Sign Up
Harmony	WAKIX	pitolisant hydrochloride	TABLET;ORAL	211150-002	Aug 14, 2019		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,486,947

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	05290727	Apr 1, 2005

PCT Information
PCT Filed	March 30, 2006	PCT Application Number:	PCT/IB2006/000739
PCT Publication Date:	October 05, 2006	PCT Publication Number:	WO2006/103546

International Family Members for US Patent 8,486,947

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006228413	⤷ Sign Up
Brazil	PI0612216	⤷ Sign Up
Canada	2603656	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.